INmune Bio (INMB) IPO Opens at $8.44
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “INMB”
February 4, 2019 8:55 AM ESTLA JOLLA, CA, Feb. 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (INmune or the Company), an immunotherapy company focused on developing therapies that harness the patients innate immune system to fight disease, today announced that the Companys common stock is expected to commence trading on The Nasdaq Capital Market, on Monday, February 4, 2019 under the ticker symbol INMB.
On February 1, 2019, INmune closed its initial public offering (IPO) of 1,020,560 shares of its common stock at of $8.00 per share for a total of $8,166,560 in gross proceeds before placement agent fees and offering expenses.
Univest Securities, LLC... More
INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “INMB”
February 4, 2019 8:55 AM ESTLA JOLLA, CA, Feb. 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (INmune or the Company), an immunotherapy company focused on developing therapies that harness the patients innate immune system to fight disease, today announced that the Companys common stock is expected to commence trading on The Nasdaq Capital Market, on Monday, February 4, 2019 under the ticker symbol INMB.
On February 1, 2019, INmune closed its initial public offering (IPO) of 1,020,560 shares of its common stock at of $8.00 per share for a total of $8,166,560 in gross proceeds before placement agent fees and offering expenses.
Univest... More



